Biosimilars

What are biosimilars? The Pharmacy Times® Biosimilars resource center keeps those in the space up to date with the latest clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.
 

What can we help you find?
[[thumbnail_alt_text]]
FDA Approves Biosimilar to Humira
Mylan plans to launch adalimumab-fkjp in the United States in July 2023.
[[thumbnail_alt_text]]
FDA Approves Oncology Supportive Care Biosimilar
FDA officials based their approval on the review of data and evidence that demonstrated a close similarity between pegfilgrastim-apgf and its reference product.
[[thumbnail_alt_text]]
Impact of Competition of Biosimilars on Biologics
Considerations of biosimilars as a valuable asset to the health care system, the impact of the competition biosimilars have on biologics regarding price and rebates, and final thoughts.
[[thumbnail_alt_text]]
Economic Impact of Biosimilars
A discussion on the pricing of biosimilars and factors that limit the cost-savings potential.
[[thumbnail_alt_text]]
Myths and Misconceptions on Biosimilars
Common myths and misconceptions for biosimilars are explored.
[[thumbnail_alt_text]]
Raising Patient Awareness of Biosimilar Products
The panel discusses patient awareness of biosimilar products and whether they provide supplemental patient education through patient information sheets.
[[thumbnail_alt_text]]
Role of Clinical Pharmacists in Switching Biosimilars
The scope of the clinical pharmacist is discussed in switching a patient over to a preferred biosimilar along with the role of specialty pharmacy.
[[thumbnail_alt_text]]
Limiting Quantity of Available Biosimilars
A discussion on limiting the number of biosimilars available for the same product at an institution regarding inventory, fridge space, and safety.
[[thumbnail_alt_text]]
Switching Treatment From Biologics to Biosimilars
The panel explores the appropriateness of switching from a biologic to a biosimilar through consideration of factors such as the curative vs noncurative setting, the EMR system, and patient education.
[[thumbnail_alt_text]]
Expert Panel Examines Biosimilar Pathway
The FDA does not usually require animalstudies for biosimilars; therefore, the process can move directly to pharmacokinetic and pharmacodynamic studies.
[[thumbnail_alt_text]]
Recommending Biosimilars vs Biologics: Patient Factors
Considerations for certain patient factors when recommending a biosimilar over a biologic to treat a patient.
[[thumbnail_alt_text]]
Biosimilar Decision-Making Process in Clinical Settings
Marc Earl, PharmD, BCOP, and Tim Peterson, PharmD, BCOP, share their clinical experience with P&T committee decisions, the cost of switching, and the payor selection process for a patient.

The Pharmacy Times® Biosimilars condition center provides a source of all the latest clinical information, with articles covering updates from the robust pipeline of biosimilars, and the newest data from all phases of clinical trials and studies. 

Among its other resources are a wealth of videos including interviews with thought leaders and experts in biosimilars, and moderated panel discussions about the best practices and key methods for treating complex cases, utilizing the newest biologic medical products replicating medical products originally manufactured by popular companies.